PCOS Basics12 min read
Understanding PCOS: A Complete Guide
Learn about the causes, symptoms, and management strategies for Polycystic Ovary Syndrome
Read MorePCOS Science9 min read
Rotterdam Criteria: 20 Years Later
Evaluating the current diagnostic criteria for PCOS and proposed updates based on two decades of research.
What You'll Learn
- The history and purpose of the Rotterdam Criteria
- How the criteria are used to diagnose PCOS
- Recent debates and updates from leading experts
- Proposed improvements to current diagnostic frameworks
Understanding the Rotterdam Criteria
Introduced in 2003 by a consensus of the European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM), the Rotterdam Criteria expanded the diagnostic landscape for PCOS. Unlike earlier definitions that focused solely on hyperandrogenism and ovulatory dysfunction, the Rotterdam Criteria recognized a broader phenotype spectrum. A diagnosis is made if two of the following three features are present: (1) oligo- or anovulation, (2) clinical and/or biochemical signs of hyperandrogenism, and (3) polycystic ovarian morphology on ultrasound.
The Three Diagnostic Pillars
These three criteria encompass a wide variety of PCOS phenotypes, enabling diagnosis in a broader range of women, including those without visible symptoms of hyperandrogenism or irregular cycles.
Ovulatory Dysfunction
Infrequent or absent ovulation leading to irregular menstrual cycles and infertility.
Hyperandrogenism
Elevated levels of male hormones causing symptoms such as acne, hirsutism, and hair thinning.
Polycystic Ovarian Morphology
Ultrasound showing 12 or more follicles in each ovary or increased ovarian volume.
Clinical Application & Global Variability
While the Rotterdam Criteria have been adopted worldwide, their application varies across regions. In some countries, clinicians continue to rely on the NIH 1990 definition, which requires both hyperandrogenism and ovulatory dysfunction. This variability can lead to inconsistent diagnoses and complicates research and treatment comparisons across populations.
Criticisms and Challenges
Despite its wide adoption, the Rotterdam Criteria have been subject to several criticisms over the years. Here are the key concerns voiced by researchers and clinicians:
Overdiagnosis Risk
Some argue that including women with only ultrasound findings but no clinical symptoms may lead to overdiagnosis and unnecessary anxiety.
Subjective Assessments
Clinical hyperandrogenism is assessed visually, which can be subjective and vary with ethnicity and experience.
Lack of Biomarkers
There is no definitive biomarker for PCOS, making the diagnosis reliant on exclusion and clinical judgment.
Evolving Perspectives: New Guidelines
In 2018, international guidelines by the Australian NHMRC and ESHRE updated the diagnostic approach by recommending a follicle count threshold of 20 using high-resolution ultrasound, reflecting advances in imaging technology. Additionally, the guidelines emphasize a life-course approach to diagnosis and management, recognizing the metabolic and psychological dimensions of PCOS beyond fertility.
Proposed Future Improvements
Based on recent expert recommendations, future diagnostic models may consider adding more dimensions to better reflect PCOS complexity:
Potential Additions
- Insulin resistance assessment
- Chronic low-grade inflammation markers
- Androgen index calibration by ethnicity
- Psychosocial health evaluations
Improved Tools
- Machine learning to analyze symptom clusters
- Non-invasive hormone diagnostics
- Integration of genetic markers
- Longitudinal symptom tracking app like ours Aora]
Related Articles
Take Control of Your PCOS Journey
Download Aora to track symptoms, monitor cycles, and get personalized insights